ALK is a global research-driven pharmaceutical company focusing on allergy prevention, diagnosis and treatment. Our mission is to improve the quality of life of people suffering from allergy by developing pharmaceutical products targeted at the cause of allergy. ALK is the world leader in allergy immunotherapy (allergy vaccination) - a unique treatment of the underlying cause of allergy. The treatment induces a protective immune response that provides sustained symptom relief and reduces the risk of developing asthma. ALK provides allergy immunotherapy administered as injections, sublingual drops and tablets, the most recent, best documented and most convenient treatment for patients. The product portfolio also includes an adrenaline pen for the treatment of severe allergic reactions (anaphylaxis). Every year, ALK invests approx. 20% of revenue in research and development aimed at developing new, evidence based allergy immunotherapy products. Our R&D pipeline includes tablet based allergy immunotherapy products against ragweed, house dust mite and tree pollen allergy. ALK has entered into partnership agreements with Merck and Torii Pharmaceutical Co., Ltd. to develop, register and commercialise tablets in North America and Japan. ALK has approx. 1,850 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B).

Show more
TypePublic
HQHørsholm, DK
Founded1923
Size (employees)2,313 (est)
Websitealk.net
ALK-Abello was founded in 1923 and is headquartered in Hørsholm, DK
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

ALK-Abello Office Locations

ALK-Abello has an office in Hørsholm
Hørsholm, (HQ)
1 Bøge Alle
Show all (1)
Report incorrect company information

ALK-Abello Online and Social Media Presence

Embed Graph
Report incorrect company information

ALK-Abello News and Updates

Allergy Immunotherapies (Allergy Immunotherapy) Global Market 2018: Key Players – ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, HAL

Allergy Immunotherapies (Allergy Immunotherapy) -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

ALK-Abello Blogs

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Tuesday, November 13, 2018https://globenewswire.com/NewsRoom/ReleaseNg/400236097/en/1 Nasdaq ID:  1843812

Release date of nine-month interim report (Q3) 2018 and audio cast

Monday, November 5, 2018https://globenewswire.com/NewsRoom/ReleaseNg/400223182/en/1 Nasdaq ID:  1837292

ALK-Abello Company Life and Culture

Report incorrect company information

ALK-Abello Frequently Asked Questions

  • When was ALK-Abello founded?

    ALK-Abello was founded in 1923.

  • How many employees does ALK-Abello have?

    ALK-Abello has 2,313 employees.

  • Who are ALK-Abello competitors?

    Competitors of ALK-Abello include GRAIL, XTuit Pharmaceuticals and Navidea Biopharmaceuticals.

  • Where is ALK-Abello headquarters?

    ALK-Abello headquarters is located at 1 Bøge Alle, Hørsholm.

  • Where are ALK-Abello offices?

    ALK-Abello has an office in Hørsholm.

  • How many offices does ALK-Abello have?

    ALK-Abello has 1 office.